Boehringer Ingelheim has returned to Kyowa Kirin for a 640 million euro ($743 million) deal for a preclinical program the German pharma hopes will offer a new autoimmune disease option. | Boehringer ...
The licensed small molecule program aims to address significant unmet needs forautoimmune diseases. Programadds toBoehringer’s pipeline and its ...
Boehringer Ingelheim licences a novel small-molecule treatment from Kyowa Kirin for fibro-inflammatory and autoimmune diseases in a deal worth up to €410 million.
German family-owned pharma major Boehringer Ingelheim and AimedBio, a Korean biotech company pioneering antibody-drug conjugate (ADC) technology, announced a global collaboration and licensing ...
Mergers and acquisitions are not just for Big Pharma. A new report from Leerink Partners takes a stab at identifying the ...
As pharmaphorum reported during ESMO 2025, fresh from a return to oncology with the FDA approval of zongertinib as a ...
Boehringer Ingelheim announced an agreement with Quallent Pharmaceuticals, a private label pharmaceutical distributor, to help expand patient access to citrate-free adalimumab-adbm, Boehringer’s ...
Boehringer Ingelheim unveiled its evolved company brand this week, featuring the corporate claim: “Life forward.” The German pharma giant said the claim builds upon the company’s purpose of ...
Physical function decline is an increasingly recognised concern among individuals with long-term conditions such as Type 2 ...
INGELHEIM, Germany & SAN DIEGO--(BUSINESS WIRE)--Boehringer Ingelheim today announced the signing of an option to acquire Trutino Biosciences Inc. (the “Transaction”), a San Diego-based biotech ...
INGELHEIM, Germany & MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Boehringer Ingelheim announced today a collaborative agreement with Google Quantum AI (Google), focusing on researching and implementing ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback